BioSpace News Archive

As providers in the healthcare industry continue work to develop effective treatments for COVID-19, SCL Health is advancing critical work with the antibody therapy known as Convalescent Plasma (CP) transfusions.

Q30 Innovations today announced an agreement with the United States Army Medical Materiel Development Activity (USAMMDA) to study its innovative Q-Collar for the potential to be used by U.S. Service Members that may be at risk of traumatic brain injury.

Baxter International Inc. (NYSE:BAX), a global leader in acute care, announced it has received emergency use authorization (EUA) from the U.S. FDA for the company’s Oxiris filter set to treat patients who have confirmed COVID-19 and have been admitted to the intensive care unit (ICU) with confirmed or imminent respiratory failure in need of blood purification therapy to reduce pro-inflammatory cytokine levels, including use in continuous renal replacement therapy (CRRT).

The Canadian Medical Association applauds announcement by the federal government that it will invest $1.1 billion in a National Medical Strategy to tackle COVID-19.

Merit Medical Systems, Inc. (NASDAQ: MMSI), a leading manufacturer and marketer of proprietary disposable devices used in interventional, diagnostic and therapeutic procedures, particularly in cardiology, radiology, oncology, critical care and endoscopy, today announced revenue of $243.5 million for the quarter ended March 31, 2020, an increase of 2.2% over revenue of $238.3 million for the quarter ended March 31, 2019.

Dynavax Technologies Corporation, a biopharmaceutical company focused on developing and commercializing novel vaccines, will report first quarter 2020 financial results on Thursday, May 7, 2020, after the U.S. financial markets close.

Tabula Rasa HealthCare, Inc., will release its first quarter 2020 operating results Thursday, May 7, 2020, after market close, on the investor relations section of TRHC’s website at ir.trhc.com.

Innovent Biologics, Inc. (“Innovent”) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, autoimmune, metabolic and other major diseases, today jointly announced with Eli Lilly and Company (“Lilly”, NYSE: LLY) that the National Medical Products Administration (NMPA) of China has accepted the supplemental New Drug Application (sNDA) for Tyvyt®

GlaxoSmithKline plc (LSE/NYSE:GSK) today announced data from an updated analysis of the GARNET trial, which demonstrated that dostarlimab, an investigational anti-programmed death-1 (PD-1) monoclonal antibody, provided clinically meaningful results in women with recurrent or advanced mismatch repair-deficient (dMMR) endometrial cancer who progressed on or after a platinum-based regimen.

Notice is hereby given that Faruqi & Faruqi, LLP has filed a class action lawsuit in the United States District Court for the Southern District of New York, Case No. 1:20-cv-02847 on behalf of shareholders of Progenics Pharmaceuticals, Inc. (“Progenics” or the “Company”) (NASDAQ:PGNX) who have been harmed by Progenics’ and its board of directors’ (the “Board”) alleged violations of Sections 14(a) and 20(a)